Radioiodine(131I) has been used for the treatment of Graves' hyperthyroidism since the late 1940's and is now generally regarded as the treatment of choice for Graves' hyperthyroidism who do not remit following a course of antithyroid drugs. But
for the
dose given several different protocols have been described by different centres, each attempting to reduce the incidence of long-term thyroid failure while maintaining an acceptable rate of control of Graves' hyperthyroidism. To evaluate
short-term
follow up of fixed-dose and calculated-dose 131I therapy for Graves' hyperthyroidism, we studied clinical outcomes of 83 patients with Graves' hyperthyroidism treated with fixed-dose (10 mCi) or calculated-dose 131I therapy.
@ES The results were as follows:
@EN 1) the romission rate of Graves' hyperthyroidism was 81.3% in fixed-dose and 82.4% in calculated-dose group after 3 years of 131I ablation.
2) The cumulative incidence of hypothyroidism was not different between fixed-dose and calculated-dose group after 3 years of 131I ablation (Fixed-dose vs. calculated-dose: 28.6% vs. 17.8% at 1 year, 31.3% vs. 25.5% at 2 years. 40.6 vs. 29.2% at
3
years).
3) The remission rate or incidence of cumulative hypothyroidism after 3 years was not different between fixed-dose and calculated-dose group in each ages and sex, but all 3 patients less than 20 years old had fallen in hypothyroidism after 131I
ablation.
4) There were no significant statistical differences of other related pretreatment variables (age, sex, thyroid function tests, RAIU, goiter size) between fixed-dose and calculated-dose group
In conclusion, there were no significant differences in remission rate and the incidence of hypothyroidism between the fixed-dose and the calculated-dose group We suggest that noncalculated fixed low dose (6 mCi) radioiodine therapy could be
given
for
the treatment of Graves' hyperthyroidism
(J Kor Soc Endocrinol 7:358~363, 1992).
|